KOL Event on aneurysmal Subarachnoid Hemorrhage (aSAH) ...

GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported fiscal year (FY) third quarter results following a series of announcements regarding conference participation, ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, ...

10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a ...

GTx-104 reduced clinically significant hypotension by 19% versus oral nimodipine (28% vs. 35%) in aSAH patients. 54% of GTx-104 patients maintained 95%+ relative dose intensity versus 8% on oral ...

Investorideas , a global news source and expert investing resource, announces today's roundup of stocks added to the biotech stock directory.

Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...

The upfront net proceeds from this private placement will also be allocated for general corporate purposes. The injectable formulation of nimodipine is in clinical stages, being developed for IV ...